MYBPC3

Summary

MYBPC3 (myosin binding protein C3, HGNC:7551) is a protein-coding gene on chromosome 11p11.2, encoding Myosin-binding protein C, cardiac-type (Q14896). Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. It is haploinsufficient (ClinGen: sufficient evidence).

MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3 is expressed exclusively in heart muscle and is a key regulator of cardiac contraction. Mutations in this gene are a frequent cause of familial hypertrophic cardiomyopathy.

Source: NCBI Gene 4607 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hypertrophic cardiomyopathy (Definitive, ClinGen) — +7 more curated relationships
• GWAS associations: 64
• Clinical variants (ClinVar): 4,702 total — 678 pathogenic, 234 likely-pathogenic
• Phenotypes (HPO): 48
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• MANE Select transcript: NM_000256

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7551
Approved symbol	MYBPC3
Name	myosin binding protein C3
Location	11p11.2
Locus type	gene with protein product
Status	Approved
Aliases	FHC, cMyBP-C
Ensembl gene	ENSG00000134571
Ensembl biotype	protein_coding
OMIM	600958
Entrez	4607

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 nonsense_mediated_decay

ENST00000399249, ENST00000544791, ENST00000545968

RefSeq mRNA: 1 — MANE Select: NM_000256 NM_000256

CCDS: CCDS53621

Canonical transcript exons

ENST00000545968 — 35 exons

Exon	Start	End
ENSE00000921269	47331845	47331881
ENSE00000921270	47332072	47332258
ENSE00000921271	47332566	47332702
ENSE00000921272	47332814	47332973
ENSE00000921273	47333194	47333333
ENSE00000921274	47333557	47333752
ENSE00000921275	47333922	47334010
ENSE00000921276	47335042	47335209
ENSE00001098039	47347426	47347479
ENSE00001098040	47343021	47343145
ENSE00001098044	47347857	47347905
ENSE00001098047	47338520	47338679
ENSE00001098049	47343492	47343624
ENSE00001098052	47342830	47342935
ENSE00001098053	47351239	47351505
ENSE00001098054	47346207	47346370
ENSE00001098055	47347651	47347680
ENSE00001098057	47350014	47350112
ENSE00001098058	47341003	47341032
ENSE00001098059	47342578	47342744
ENSE00001098062	47341991	47342156
ENSE00001129990	47331406	47331716
ENSE00001130046	47337391	47337579
ENSE00001130054	47337690	47337794
ENSE00001130066	47339324	47339404
ENSE00001130073	47339651	47339790
ENSE00001130082	47341138	47341244
ENSE00001130136	47348424	47348541
ENSE00001130142	47349774	47349922
ENSE00001130147	47350502	47350615
ENSE00001304474	47352623	47352702
ENSE00001799700	47343260	47343262
ENSE00002266002	47346627	47346644
ENSE00002288859	47347027	47347029
ENSE00003694001	47335877	47336011

Expression profiles

Bgee: expression breadth ubiquitous, 149 present calls, max score 99.90.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 3.9568 / max 1299.2100, expressed in 42 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119567	3.9276	42
206275	0.0293	12

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	99.90	gold quality
right atrium auricular region	UBERON:0006631	99.65	gold quality
cardiac atrium	UBERON:0002081	99.63	gold quality
left ventricle myocardium	UBERON:0006566	99.45	gold quality
cardiac ventricle	UBERON:0002082	99.34	gold quality
heart left ventricle	UBERON:0002084	99.34	gold quality
heart right ventricle	UBERON:0002080	99.29	gold quality
cardiac muscle of right atrium	UBERON:0003379	99.25	gold quality
myocardium	UBERON:0002349	99.04	gold quality
vena cava	UBERON:0004087	96.51	gold quality
heart	UBERON:0000948	94.51	gold quality
triceps brachii	UBERON:0001509	84.35	gold quality
gluteal muscle	UBERON:0002000	83.88	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	81.11	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.21	gold quality
tendon of biceps brachii	UBERON:0008188	80.08	gold quality
biceps brachii	UBERON:0001507	79.74	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	77.98	gold quality
vastus lateralis	UBERON:0001379	77.49	gold quality
sperm	CL:0000019	76.92	gold quality
male germ cell	CL:0000015	76.90	gold quality
gingival epithelium	UBERON:0001949	76.75	gold quality
quadriceps femoris	UBERON:0001377	76.65	gold quality
parotid gland	UBERON:0001831	76.40	gold quality
gingiva	UBERON:0001828	76.38	gold quality
Brodmann (1909) area 10	UBERON:0013541	76.32	gold quality
blood	UBERON:0000178	75.95	gold quality
endometrium epithelium	UBERON:0004811	75.93	gold quality
body of tongue	UBERON:0011876	75.74	gold quality
pericardium	UBERON:0002407	75.50	silver quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-2	yes	3693.89
E-ANND-3	yes	3.70
E-MTAB-11268	no	8407.69

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

6 targeting MYBPC3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-6793-3P	97.66	65.78	1084
HSA-MIR-4800-5P	97.22	65.91	324

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• Left ventricular hypertrophy can be a late manifestation of hypertrophic cardiomyopathy due to cardiac myosin-binding protein C mutations. (PMID:11955864)
• Results suggest that the cardiac myosin-binding protein C gene (MYBPC3) is the predominant gene for hypertrophic cardiomyopathy in eastern Finland. (PMID:12110947)
• Haplotype analysis suggested that the two most common variants (MYBPC3-Gln1061X and TPM1-Asp175Asn) were founder mutations. (PMID:15000344)
• NMR assignment of domain C1 of the N-terminal myosin-binding site of human cardiac myosin binding protein C (PMID:15213454)
• MYBPC3-HCM virtually mimicked the phenotype of those with mutations in the beta-myosin heavy chain. Patients with multiple mutations had the most severe phenotype. (PMID:15519027)
• Our results point out that GG genotype of MYBPC3 might be a genetic risk factor for the expression of cardiac hypertrophic phenotype in the patients with hypertrophic cardiomyopathy. (PMID:15737656)
• Truncated cMyBP-C resulting from human MYBPC3 mutations are rapidly and quantitatively degraded by the ubiquitin-proteasome system, which in turn may competitively inhibit breakdown of other proteasome substrates. (PMID:15769446)
• role of MYBPC3 mutations in hypertrophic cardiomyopathy; three new mutations in three families (V771M, V342D, and A627V)were found; findings suggest a dosage effect for mutations at the MYPBC3 gene (PMID:16004897)
• mutation in the TNNT2 gene with aggravating mutation in the MYBPC3 gene causing restrictive cardiomyopathy in a child (PMID:16651346)
• lution structure of one part of the N-terminal binding site, the third immunoglobulin domain of the cardiac isoform of human MyBP-C (cC2) together with a model of its interaction with myosin (PMID:17192269)
• The compromised contractile function of the failing heart might be in part attributable to reduced cMyBP-C phosphorylation levels. (PMID:17560599)
• identified a novel homozygous mutation, c.3330 + 2T > G, in the splice-donor site of MYBPC3 intron 30, resulting in skipping of the 140-bp exon 30, which led to a frame shift and premature stop codon in exon 31; phenotype found in Amish communities (PMID:17937428)
• Screening of the exons in hypertrophic cardiomyopathy revealed two variations - one novel frame shift mutation in exon 19 at the nucleotide position 11577-11578 and one novel single nucleotide polymorphism (SNP) in codon 1093 of exon 31. (PMID:18273486)
• Four mutations in the MYBPC3 gene are found to be associated with hypertrophic cardiomyopathy; all four result in premature termination codons, which suggests that haploinsufficiency is a pathogenic mechanism of this type of mutation. (PMID:18337725)
• The structure of the immunoglobulin-like C1 domain of MyBP-C was solved by X-ray crystallography to a resolution of 1.55 A. (PMID:18374358)
• Homozygous mutations in the MYBPC3 gene have been identified as the cause of severe infantile HCM among the Amish population. (PMID:18467358)
• Diffraction data from the C1 domain of cMyBP-C were extended to 1.30 A resolution, where the of the diffraction data crosses 2.0, using intense synchrotron radiation. (PMID:18560154)
• MyBP-C is a highly phosphorylated protein in vivo; diminished MyBP-C phosphorylation is a feature of both end-stage heart failure and hypertrophic cardiomyopathy. (PMID:18573260)
• PKA phosphorylation of cMyBP-C accelerates crossbridge kinetics and loss of this regulation leads to cardiac dysfunction. (PMID:18802026)
• Mutations in MYBPC3 should be considered a frequent cause of hypertrophic cardiomyopathy in Poland. (PMID:18803133)
• the missense MYBPC3 mutation E334K destabilizes its protein and may contribute to cardiac dysfunction in hypertrophic cardiomyopathy through impairment of the ubiquitin-proteasome system. (PMID:18929575)
• MYBPC3 mutations can be associated with cardiac events such as progressive heart failure, stroke and sudden death even at younger age (PMID:18957093)
• MYBPC3 mutation was found involved in hypertrophic cardiomyopathy. (PMID:19035361)
• A deletion of 25 bp in the gene encoding cardiac myosin binding protein C (MYBPC3) that is associated with heritable cardiomyopathies and an increased risk of heart failure in Indian populations. (PMID:19151713)
• Frameshift MYBPC3 mutations cause haploinsufficiency, deranged phosphorylation of contractile proteins, and reduced maximal force-generating capacity of cardiomyocytes (PMID:19273718)
• Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. (PMID:19356534)
• A new ligand of obscurin at the M-band, MyBP-C slow variant-1 and suggest that their interaction contributes to the assembly of M-and A-bands, is identified. (PMID:19403693)
• description of a family in which some experienced early development of systolic & diastolic dysfunction & others experienced sudden death at young age; identified a novel homozygous mutation (IVS6+5G>A) in MYBPC3 gene that explained the phenotype (PMID:19406073)
• The lowered relative level of full length protein in both truncation and missense MYBPC3 mutations argues strongly that haploinsufficiency is sufficient to cause hypertrophic cardiomyopathy. (PMID:19574547)
• Large deletions and duplications in MYBPC3 do not appear to play a major role in the pathogenesis of hypertrophic cardiomyopathy. (PMID:19666196)
• increased myofilament protein levels in patients with MYBPC3-mediated HCM suggest a poison peptide mechanism (PMID:19808356)
• atrogin-1 specifically targets truncated M7t-cMyBP-C, but not WT-cMyBP-C, for proteasomal degradation and that MuRF1 indirectly reduces cMyBP-C levels by regulating the transcription of myosin heavy chain. (PMID:19850579)
• Predictive genetic testing in hypertrophic cardiomyopathy families and cardiological evaluation on the presence of HCM and risk factors for sudden cardiac death are justified in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers (PMID:20019025)
• MYBPC3 mutation is presented in a small portion of Han Chinese patients with hypertrophic cardiomyopathy. (PMID:20021930)
• cMYBPC3 might be the disease-causing gene in Chinese patients with hypertrophic cardiomyopathy. (PMID:20128375)
• Report for the first time that there are four PKA phosphorylation sites in both murine and human M-domains. (PMID:20151718)
• The novel S236G mutation in MYBPC3 gene was a hot-spot mutation in Chinese patients with hypertrophic cardiomyopathy. (PMID:20193176)
• Results indicate that the MYBPC3 deletion is primarily found among Indian populations and that its distribution is consistent with genome-wide patterns of variation in India. (PMID:20201939)
• The mutations in MYBPC3 cause when a genetic cause can be identified, which has estimated to occur in 42% of hypertrophic cardiomyopathy. (PMID:20215591)
• The novel mutation S297X in MYBPC3 causes hypertrophic cardiomyopathy in a broad range of ages and heterogeneous clinical manifestations, though the clinical course in patients with this mutation seems to be benign. (PMID:20350521)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mybpc3	ENSDARG00000011615
mus_musculus	Mybpc3	ENSMUSG00000002100
rattus_norvegicus	Mybpc3	ENSRNOG00000012307

Paralogs (11): MYOM2 (ENSG00000036448), FNDC3B (ENSG00000075420), MYBPC2 (ENSG00000086967), MYOM1 (ENSG00000101605), FNDC3A (ENSG00000102531), OBSL1 (ENSG00000124006), MYBPH (ENSG00000133055), MYOM3 (ENSG00000142661), IGSF22 (ENSG00000179057), MYBPC1 (ENSG00000196091), MYBPHL (ENSG00000221986)

Protein

Protein identifiers

Myosin-binding protein C, cardiac-type — Q14896 (reviewed: Q14896)

Alternative names: C-protein, cardiac muscle isoform

All UniProt accessions (3): A8MXZ9, Q14896, F5GZR4

UniProt curated annotations — full annotation on UniProt →

Function. Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. It may modulate muscle contraction or may play a more structural role.

Post-translational modifications. Substrate for phosphorylation by PKA and PKC. Reversible phosphorylation appears to modulate contraction. Polyubiquitinated.

Disease relevance. Cardiomyopathy, familial hypertrophic, 4 (CMH4) [MIM:115197] A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. The disease is caused by variants affecting the gene represented in this entry. Cardiomyopathy, dilated, 1MM (CMD1MM) [MIM:615396] A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. The disease is caused by variants affecting the gene represented in this entry. MYBPC3 mutations may be involved in restrictive cardiomyopathy (RCM), a rare non-ischemic myocardial disease. RCM is characterized by restrictive ventricular-filling physiology in the presence of normal or reduced diastolic and/or systolic volumes (of 1 or both ventricles), biatrial enlargement, and normal ventricular wall thickness. Left ventricular non-compaction 10 (LVNC10) [MIM:615396] A form of left ventricular non-compaction, a cardiomyopathy due to myocardial morphogenesis arrest and characterized by a hypertrophic left ventricle, a severely thickened 2-layered myocardium, numerous prominent trabeculations, deep intertrabecular recesses, and poor systolic function. Clinical manifestations are variable. Some affected individuals experience no symptoms at all, others develop heart failure. In some cases, left ventricular non-compaction is associated with other congenital heart anomalies. LVNC10 is an autosomal dominant condition. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the immunoglobulin superfamily. MyBP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14896-1	1	yes
Q14896-2	2

RefSeq proteins (1): NP_000247* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR003961	FN3_dom	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR040849	MyBP-C_THB	Domain
IPR050964	Striated_Muscle_Regulatory	Family

Pfam: PF00041, PF07679, PF18362

UniProt features (182 total): sequence variant 92, strand 48, domain 10, modified residue 10, helix 6, binding site 4, turn 4, sequence conflict 3, chain 1, region of interest 1, compositionally biased region 1, disulfide bond 1, splice variant 1

Structure

Experimental structures (PDB)

17 structures.

PDB	Method	Resolution (Å)
3CX2	X-RAY DIFFRACTION	1.3
2V6H	X-RAY DIFFRACTION	1.55
7LRG	ELECTRON MICROSCOPY	6.1
8G4L	ELECTRON MICROSCOPY	6.4
7TIJ	ELECTRON MICROSCOPY	8
7TIT	ELECTRON MICROSCOPY	8
7TJ7	ELECTRON MICROSCOPY	8
6G2T	ELECTRON MICROSCOPY	9
6CXI	ELECTRON MICROSCOPY	11
6CXJ	ELECTRON MICROSCOPY	11
1GXE	SOLUTION NMR
1PD6	SOLUTION NMR
2AVG	SOLUTION NMR
2K1M	SOLUTION NMR
2MQ0	SOLUTION NMR
2MQ3	SOLUTION NMR
5K6P	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14896-F1	79.43	0.37

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 208; 210; 223; 225

Post-translational modifications (10): 1, 47, 275, 284, 304, 311, 427, 550, 607, 1241

Disulfide bonds (1): 436–443

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-390522	Striated Muscle Contraction
R-HSA-397014	Muscle contraction

MSigDB gene sets: 224 (showing top): GOBP_CARDIAC_CHAMBER_DEVELOPMENT, MULLIGHAN_NPM1_SIGNATURE_3_UP, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_CARDIAC_CHAMBER_MORPHOGENESIS, MAZ_Q6, ROVERSI_GLIOMA_COPY_NUMBER_UP, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_SARCOMERE_ORGANIZATION, GNF2_MYL3, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_REGULATION_OF_STRIATED_MUSCLE_CONTRACTION, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_REGULATION_OF_MUSCLE_CONTRACTION

GO Biological Process (8): heart morphogenesis (GO:0003007), regulation of striated muscle contraction (GO:0006942), cell adhesion (GO:0007155), regulation of muscle filament sliding (GO:0032971), sarcomere organization (GO:0045214), ventricular cardiac muscle tissue morphogenesis (GO:0055010), cardiac muscle contraction (GO:0060048), regulation of cardiac muscle cell contraction (GO:0086004)

GO Molecular Function (9): ATPase activator activity (GO:0001671), actin binding (GO:0003779), structural constituent of muscle (GO:0008307), myosin binding (GO:0017022), titin binding (GO:0031432), myosin heavy chain binding (GO:0032036), identical protein binding (GO:0042802), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (8): cytosol (GO:0005829), striated muscle myosin thick filament (GO:0005863), C zone (GO:0014705), sarcomere (GO:0030017), M band (GO:0031430), A band (GO:0031672), cardiac myofibril (GO:0097512), myosin filament (GO:0032982)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Muscle contraction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoskeletal protein binding	3
regulation of muscle contraction	2
striated muscle contraction	2
regulation of actin filament-based movement	2
sarcomere	2
A band	2
myofibril	2
heart development	1
animal organ morphogenesis	1
cellular process	1
muscle filament sliding	1
regulation of intracellular transport	1
myofibril assembly	1
actomyosin structure organization	1
cardiac ventricle morphogenesis	1
ventricular cardiac muscle tissue development	1
cardiac muscle tissue morphogenesis	1
heart contraction	1
regulation of cardiac muscle contraction	1
cardiac muscle cell contraction	1
ATP-dependent activity	1
molecular function activator activity	1
structural molecule activity	1
myosin binding	1
protein binding	1
cation binding	1
binding	1
cytoplasm	1
muscle myosin complex	1
myosin filament	1
myofilament	1
myosin complex	1
supramolecular fiber	1

Protein interactions and networks

STRING

1760 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYBPC3	TTN	Q8WZ42	987
MYBPC3	MYH7	P12883	976
MYBPC3	TNNT2	P45379	972
MYBPC3	TNNI3	P19429	966
MYBPC3	CSRP3	P50461	934
MYBPC3	TPM1	P09493	930
MYBPC3	MYL3	P08590	923
MYBPC3	ACTC1	P04270	919
MYBPC3	MYL2	P10916	892
MYBPC3	MYH6	P13533	886
MYBPC3	PRKAG2	Q9UGJ0	867
MYBPC3	TCAP	O15273	862
MYBPC3	CALM1	P02593	860
MYBPC3	CALML3	P27482	851
MYBPC3	CALML5	Q9NZT1	851

IntAct

26 interactions, top by confidence:

A	B	Type	Score
ACTC1	MYBPC3	psi-mi:“MI:0915”(physical association)	0.550
MYH7	MYBPC3	psi-mi:“MI:0915”(physical association)	0.550
MYBPC3	MYH7	psi-mi:“MI:0915”(physical association)	0.550
MYBPC3	ACTC1	psi-mi:“MI:0915”(physical association)	0.550
PDE4DIP	MYBPC3	psi-mi:“MI:0915”(physical association)	0.540
MYBPC3	PDE4DIP	psi-mi:“MI:0403”(colocalization)	0.540
MYBPC3	PDE4DIP	psi-mi:“MI:0915”(physical association)	0.540
MYBPC3	MYBPC3	psi-mi:“MI:0915”(physical association)	0.530
MYBPC3	MYBPC3	psi-mi:“MI:0407”(direct interaction)	0.530
ACTB	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
MYZAP	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
FLNC	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
CNN1	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
PARD3	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
CCT7	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
SVIL	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
SPATA20	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
HSPB2	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
TNNI3K	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
MYBPC3	TRIM63	psi-mi:“MI:0915”(physical association)	0.370
SMURF2	MYBPC3	psi-mi:“MI:0915”(physical association)	0.370
CUL1	LGALS8	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350

BioGRID (14): MYBPC3 (Two-hybrid), MYBPC3 (Two-hybrid), MYBPC3 (Two-hybrid), MYBPC3 (Two-hybrid), MYBPC3 (Far Western), MYBPC3 (Affinity Capture-MS), MYBPC3 (Affinity Capture-MS), MYBPC3 (Affinity Capture-MS), MYBPC3 (Affinity Capture-MS), MYBPC3 (Affinity Capture-Western), TRIM63 (Two-hybrid), MYBPC3 (Affinity Capture-MS), MYBPC3 (Two-hybrid), MYBPC3 (Two-hybrid)

ESM2 similar proteins: A2AAJ9, A2ABU4, A2RUH7, B4GBH0, D3ZGQ5, O09127, O70468, O75038, O88599, O95382, P16419, P21709, P22455, P22607, P29322, P54760, P54761, P55144, P55146, P56741, P70218, P70402, Q00653, Q06418, Q13203, Q13308, Q13425, Q14896, Q15746, Q290N5, Q32P44, Q4LDD4, Q5FW53, Q5PQM4, Q5VST9, Q5VTT5, Q60750, Q61851, Q68LP1, Q80UW5

Diamond homologs: A2AAJ9, A2ABU4, O88599, P12960, P14781, P28685, P52179, P54296, P68500, P70402, P97527, P97528, Q02173, Q07409, Q12860, Q13203, Q14896, Q28106, Q2EY15, Q2VWP7, Q2VWP9, Q589G5, Q5PQM4, Q5VTT5, Q62234, Q62682, Q63198, Q7ZW34, Q86TB3, Q91ZB0, Q924C5, Q96JA1, Q96L96, Q98936, Q9P232, A0A087WV53, A2ASS6, A2CG49, A2RUH7, F1M0Z1

SIGNOR signaling

17 interactions.

A	Effect	B	Mechanism
PRKCD	up-regulates	MYBPC3	phosphorylation
PRKACA	up-regulates	MYBPC3	phosphorylation
PRKACB	up-regulates	MYBPC3	phosphorylation
PRKACG	up-regulates	MYBPC3	phosphorylation
PDE4DIP	up-regulates	MYBPC3	binding
PKA	up-regulates	MYBPC3	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

4702 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	678
Likely pathogenic	234
Uncertain significance	1911
Likely benign	1122
Benign	78

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1027653	NM_000256.3(MYBPC3):c.2132G>A (p.Trp711Ter)	Pathogenic
1069672	NC_000011.9:g.(?47364119)(47374208_?)del	Pathogenic
1069713	NM_000256.3(MYBPC3):c.3688_3691dup (p.Ser1231fs)	Pathogenic
1069832	NC_000011.9:g.(?_47353958)_47355505del	Pathogenic
1069833	NC_000011.9:g.(?47360865)(47369466_?)del	Pathogenic
1069890	NM_000256.3(MYBPC3):c.1730G>A (p.Trp577Ter)	Pathogenic
1069891	NM_000256.3(MYBPC3):c.1546G>T (p.Glu516Ter)	Pathogenic
1069892	NM_000256.3(MYBPC3):c.1420G>T (p.Glu474Ter)	Pathogenic
1069893	NM_000256.3(MYBPC3):c.1269_1282del (p.Ser424fs)	Pathogenic
1070193	NM_000256.3(MYBPC3):c.514dup (p.Ile172fs)	Pathogenic
1070637	NM_000256.3(MYBPC3):c.2012_2013insGG (p.Pro672fs)	Pathogenic
1071502	NC_000011.10:g.47350113del	Pathogenic
1072518	NM_000256.3(MYBPC3):c.718_724del (p.Glu240fs)	Pathogenic
1073146	NM_000256.3(MYBPC3):c.3424C>T (p.Gln1142Ter)	Pathogenic
1074065	NM_000256.3(MYBPC3):c.318del (p.Ala107fs)	Pathogenic
1074099	NC_000011.10:g.47335210del	Pathogenic
1074339	NM_000256.3(MYBPC3):c.2164G>T (p.Glu722Ter)	Pathogenic
1074856	NM_000256.3(MYBPC3):c.1353del (p.Glu451fs)	Pathogenic
1074858	NM_000256.3(MYBPC3):c.1048_1049del (p.Lys350fs)	Pathogenic
1074948	NM_000256.3(MYBPC3):c.3357C>G (p.Tyr1119Ter)	Pathogenic
1075725	NC_000011.9:g.(?_47363401)_47367757del	Pathogenic
1075727	NC_000011.9:g.(?47357416)(47360310_?)del	Pathogenic
1076196	NM_000256.3(MYBPC3):c.405del (p.Ser137fs)	Pathogenic
1076719	NM_000256.3(MYBPC3):c.1831G>T (p.Glu611Ter)	Pathogenic
1076969	NM_000256.3(MYBPC3):c.1839del (p.Tyr614fs)	Pathogenic
1120154	Single allele	Pathogenic
1175163	NM_000256.3(MYBPC3):c.688del (p.Gln230fs)	Pathogenic
1195305	NM_000256.3(MYBPC3):c.1900del (p.Val634fs)	Pathogenic
1208791	NM_000256.3(MYBPC3):c.1516del (p.Asp506fs)	Pathogenic
1284521	NM_000256.3(MYBPC3):c.1624+1G>A	Pathogenic

SpliceAI

5457 predictions. Top by Δscore:

Variant	Effect	Δscore
11:47332185:C:CA	donor_gain	1.0000
11:47332259:C:CC	acceptor_gain	1.0000
11:47332560:CCCTA:C	donor_loss	1.0000
11:47332561:CCTA:C	donor_loss	1.0000
11:47332562:CTA:C	donor_loss	1.0000
11:47332563:TACCT:T	donor_loss	1.0000
11:47332564:ACCTT:A	donor_loss	1.0000
11:47332565:CCTTG:C	donor_loss	1.0000
11:47332703:C:CC	acceptor_gain	1.0000
11:47332704:T:A	acceptor_loss	1.0000
11:47332810:GCAC:G	donor_loss	1.0000
11:47332811:CACCT:C	donor_loss	1.0000
11:47332813:C:CA	donor_loss	1.0000
11:47332969:CACTC:C	acceptor_gain	1.0000
11:47332971:CTC:C	acceptor_gain	1.0000
11:47332971:CTCCT:C	acceptor_loss	1.0000
11:47332973:CCT:C	acceptor_loss	1.0000
11:47332974:C:A	acceptor_loss	1.0000
11:47332981:C:CT	acceptor_gain	1.0000
11:47332982:A:T	acceptor_gain	1.0000
11:47333188:GCTCA:G	donor_loss	1.0000
11:47333190:TCACC:T	donor_loss	1.0000
11:47333191:CACCA:C	donor_loss	1.0000
11:47333192:A:AC	donor_gain	1.0000
11:47333192:ACCA:A	donor_loss	1.0000
11:47333193:C:CC	donor_gain	1.0000
11:47333221:TGTG:T	donor_gain	1.0000
11:47333329:CTTGT:C	acceptor_gain	1.0000
11:47333330:TTGT:T	acceptor_gain	1.0000
11:47333331:TGT:T	acceptor_gain	1.0000

AlphaMissense

8316 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:47332894:A:G	F1137S	1.000
11:47333268:A:G	W1086R	1.000
11:47333268:A:T	W1086R	1.000
11:47343529:A:G	W396R	1.000
11:47343529:A:T	W396R	1.000
11:47332173:A:G	L1238P	0.999
11:47332875:A:C	N1143K	0.999
11:47332875:A:T	N1143K	0.999
11:47332888:A:T	V1139D	0.999
11:47332891:C:G	R1138P	0.999
11:47332970:A:G	W1112R	0.999
11:47332970:A:T	W1112R	0.999
11:47333216:T:G	Q1103P	0.999
11:47333266:C:A	W1086C	0.999
11:47333266:C:G	W1086C	0.999
11:47333267:C:G	W1086S	0.999
11:47333620:A:C	Y1043D	0.999
11:47333726:C:A	W1007C	0.999
11:47333726:C:G	W1007C	0.999
11:47333728:A:G	W1007R	0.999
11:47333728:A:T	W1007R	0.999
11:47335119:C:G	R943P	0.999
11:47335122:A:G	F942S	0.999
11:47335944:C:A	W890C	0.999
11:47335944:C:G	W890C	0.999
11:47335946:A:G	W890R	0.999
11:47335946:A:T	W890R	0.999
11:47335957:A:T	V886D	0.999
11:47337443:G:C	N850K	0.999
11:47337443:G:T	N850K	0.999

dbSNP variants (sampled 300 via entrez): RS1000137754 (11:47339238 T>C), RS1000273869 (11:47339492 C>T), RS1000474266 (11:47337881 C>A,G,T), RS1000507420 (11:47353636 T>A,C), RS1000609568 (11:47338339 A>G), RS1000675950 (11:47332410 T>C,G), RS1000835223 (11:47336126 G>A), RS1000912631 (11:47353825 G>A), RS1000925960 (11:47348819 C>T), RS1000989674 (11:47341834 C>A,G,T), RS1001124566 (11:47334191 G>C), RS1001201185 (11:47340598 C>T), RS1001278854 (11:47340437 G>A), RS1001385542 (11:47334894 G>A,T), RS1001635661 (11:47350701 C>A,T)

Disease associations

OMIM: gene MIM:600958 | disease phenotypes: MIM:615396, MIM:115197, MIM:604169, MIM:192600, MIM:601144, MIM:115200, MIM:600996, MIM:604772, MIM:194200, MIM:107970, MIM:105210, MIM:604765, MIM:142623

GenCC curated gene-disease

Disease	Classification	Inheritance
hypertrophic cardiomyopathy 4	Definitive	Autosomal dominant
left ventricular noncompaction 10	Definitive	Autosomal dominant
hypertrophic cardiomyopathy	Definitive	Autosomal dominant
familial isolated dilated cardiomyopathy	Supportive	Autosomal dominant
atrial fibrillation	Limited	Autosomal dominant
dilated cardiomyopathy	Limited	Autosomal dominant
congenital heart disease	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (5)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
arrhythmogenic right ventricular cardiomyopathy	Limited	AD
congenital heart disease	Limited	AD
dilated cardiomyopathy	Limited	AD
hypertrophic cardiomyopathy	Definitive	AD
dilated cardiomyopathy	Limited	AR

Mondo (32): hypertrophic cardiomyopathy (MONDO:0005045), cardiomyopathy (MONDO:0004994), left ventricular noncompaction 10 (MONDO:0014163), hypertrophic cardiomyopathy 4 (MONDO:0007268), left ventricular noncompaction 1 (MONDO:0011403), familial hypertrophic cardiomyopathy (MONDO:0024573), Brugada syndrome (MONDO:0015263), dilated cardiomyopathy (MONDO:0005021), dilated cardiomyopathy 1A (MONDO:0007269), hypertrophic cardiomyopathy 1 (MONDO:0008647), left ventricular noncompaction (MONDO:0018901), mitochondrial disease (MONDO:0044970), catecholaminergic polymorphic ventricular tachycardia 1 (MONDO:0011484), long QT syndrome (MONDO:0002442), heart failure (MONDO:0005252)

Orphanet (19): Rare hypertrophic cardiomyopathy (Orphanet:217569), Familial isolated dilated cardiomyopathy (Orphanet:154), Rare cardiomyopathy (Orphanet:167848), Left ventricular noncompaction (Orphanet:54260), Rare familial disorder with hypertrophic cardiomyopathy (Orphanet:99739), Brugada syndrome (Orphanet:130), Dilated cardiomyopathy (Orphanet:217604), Familial dilated cardiomyopathy with conduction defect due to LMNA mutation (Orphanet:300751), Mitochondrial disease (Orphanet:68380), Catecholaminergic polymorphic ventricular tachycardia (Orphanet:3286), Uhl anomaly (Orphanet:3403), ATTRV30M amyloidosis (Orphanet:85447), ATTRV122I amyloidosis (Orphanet:85451), Inherited arrhythmogenic cardiomyopathy (Orphanet:247), Familial dilated cardiomyopathy (Orphanet:217607)

HPO phenotypes

48 total (30 of 48 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000407	Sensorineural hearing impairment
HP:0000969	Edema
HP:0001279	Syncope
HP:0001297	Stroke
HP:0001541	Ascites
HP:0001635	Congestive heart failure
HP:0001639	Hypertrophic cardiomyopathy
HP:0001640	Cardiomegaly
HP:0001644	Dilated cardiomyopathy
HP:0001645	Sudden cardiac death
HP:0001663	Ventricular fibrillation
HP:0001678	Atrioventricular block
HP:0001695	Cardiac arrest
HP:0001698	Pericardial effusion
HP:0001714	Ventricular hypertrophy
HP:0001727	Thromboembolic stroke
HP:0002092	Pulmonary arterial hypertension
HP:0002094	Dyspnea
HP:0002098	Respiratory distress
HP:0002240	Hepatomegaly
HP:0002326	Transient ischemic attack
HP:0002875	Exertional dyspnea
HP:0003198	Myopathy
HP:0003457	EMG abnormality
HP:0003581	Adult onset
HP:0003584	Late onset
HP:0003621	Juvenile onset
HP:0003623	Neonatal onset

GWAS associations

64 associations (top):

Study	Trait	p-value
GCST002315_3	Thrombin generation potential phenotypes	5.000000e-22
GCST004521_165	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST005232_56	Neuroticism	1.000000e-16
GCST006394_89	Intraocular pressure	1.000000e-18
GCST006923_11	Loneliness	1.000000e-07
GCST006924_13	Loneliness (MTAG)	1.000000e-08
GCST006944_48	Experiencing mood swings	1.000000e-08
GCST007269_198	Pulse pressure	4.000000e-14
GCST007825_4	Alzheimer’s disease or fasting glucose levels (pleiotropy)	3.000000e-16
GCST007930_119	Medication use (agents acting on the renin-angiotensin system)	5.000000e-13
GCST008070_129	HDL cholesterol levels	2.000000e-07
GCST008070_61	HDL cholesterol levels	9.000000e-16
GCST008070_86	HDL cholesterol levels	4.000000e-09
GCST008074_162	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	1.000000e-08
GCST008074_56	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	6.000000e-07
GCST008075_161	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	4.000000e-29
GCST008075_219	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	2.000000e-08
GCST008075_23	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	5.000000e-28
GCST008083_51	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	1.000000e-06
GCST008083_99	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	2.000000e-08
GCST008084_156	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	5.000000e-69
GCST008084_35	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	6.000000e-31
GCST008084_68	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	1.000000e-48
GCST008085_133	HDL cholesterol levels in current drinkers	2.000000e-17
GCST008085_2	HDL cholesterol levels in current drinkers	6.000000e-07
GCST008085_55	HDL cholesterol levels in current drinkers	4.000000e-22
GCST008087_31	Triglyceride levels in current drinkers	2.000000e-07
GCST008757_6	Alcohol consumption	5.000000e-14
GCST009597_53	Multiple sclerosis	1.000000e-13
GCST010002_238	Refractive error	2.000000e-14

EFO canonical traits (15, from GWAS)

EFO ID	Trait name
EFO:0005538	thrombin generation potential measurement
EFO:0007660	neuroticism measurement
EFO:0004695	intraocular pressure measurement
EFO:0007865	loneliness measurement
EFO:0008475	mood instability measurement
EFO:0005763	pulse pressure measurement
EFO:0009931	Agents acting on the renin-angiotensin system use measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004530	triglyceride measurement
EFO:0004329	alcohol drinking
EFO:0008111	diet measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004346	neuroimaging measurement
EFO:0004327	electrocardiography
EFO:0005091	monocyte count

MeSH disease descriptors (18)

Descriptor	Name	Tree numbers
D019571	Arrhythmogenic Right Ventricular Dysplasia	C14.240.400.145; C14.280.238.028; C14.280.400.145; C16.131.240.400.145
D001281	Atrial Fibrillation	C14.280.067.198; C23.550.073.198
D053840	Brugada Syndrome	C14.280.067.322; C14.280.123.250; C16.320.100
D009202	Cardiomyopathies	C14.280.238
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160
D024741	Cardiomyopathy, Hypertrophic, Familial	C14.280.238.100.500; C14.280.484.048.750.070.160.500; C16.320.160
D006323	Heart Arrest	C14.280.383
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400
D006333	Heart Failure	C14.280.434
D006627	Hirschsprung Disease	C06.198.439; C06.405.469.158.701.439; C16.131.314.439
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
D014927	Wolff-Parkinson-White Syndrome	C14.280.067.780.977; C14.280.123.750.977; C16.131.240.400.980
C563409	Arrhythmogenic Right Ventricular Dysplasia, Familial, 2 (supp.)
C565752	Cardiomyopathy, Dilated, 1i (supp.)
C566169	Cardiomyopathy, Familial Hypertrophic, 4 (supp.)
C536231	familial dilated cardiomyopathy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Myosin binding proteins

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	increases abundance, affects expression	1
Benzo(a)pyrene	decreases methylation	1
Folic Acid	affects expression	1
Isoproterenol	affects cotreatment, increases response to substance	1
Ozone	affects expression, increases abundance	1
Phenylephrine	affects cotreatment, increases response to substance	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	decreases expression	1
Sodium Selenite	decreases expression	1

Cellosaurus cell lines

46 cell lines: 44 induced pluripotent stem cell, 1 transformed cell line, 1 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A0YS	UKEi070-A	Induced pluripotent stem cell	Female
CVCL_A0YT	UKEi070-A-1	Induced pluripotent stem cell	Female
CVCL_A0YU	UKEi070-A-2	Induced pluripotent stem cell	Female
CVCL_A2PZ	GM27131	Transformed cell line	Male
CVCL_A3ZE	FJMA0001i-HCM	Induced pluripotent stem cell	Male
CVCL_A5EW	EHTJUi003-A	Induced pluripotent stem cell	Female
CVCL_A5FU	SCVIi001-A	Induced pluripotent stem cell	Male
CVCL_A5FV	SCVIi002-A	Induced pluripotent stem cell	Female
CVCL_A5VV	ICGi029-A	Induced pluripotent stem cell	Female
CVCL_B0JP	SHIPMi001-A	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

527 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00032591	PHASE4	COMPLETED	The Home INR Study
NCT00127712	PHASE4	COMPLETED	Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery
NCT00157781	PHASE4	COMPLETED	LEAF - Low Energy In Atrial Fibrillation
NCT00170313	PHASE4	TERMINATED	CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation
NCT00189319	PHASE4	COMPLETED	To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation
NCT00196144	PHASE4	COMPLETED	FFS - Far Field Sensing Test Study in Cardiac Dual Chamber Pacemakers
NCT00196157	PHASE4	UNKNOWN	Line Versus Spot Ablation in Persistent Atrial Fibrillation
NCT00196183	PHASE4	COMPLETED	Trigger- vs. Substrate-Ablation for Paroxysmal Atrial Fibrillation
NCT00196209	PHASE4	UNKNOWN	Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation
NCT00227344	PHASE4	TERMINATED	CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation
NCT00232219	PHASE4	COMPLETED	Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion
NCT00232232	PHASE4	COMPLETED	Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
NCT00232245	PHASE4	COMPLETED	Use of Fish Oils to Reduce the Frequency and Duration of Episodes of Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation.
NCT00239226	PHASE4	COMPLETED	Electrophysiologically Guided PAcing Site Selection Study
NCT00247780	PHASE4	COMPLETED	Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation
NCT00256152	PHASE4	COMPLETED	Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial
NCT00262119	PHASE4	COMPLETED	MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure
NCT00287209	PHASE4	COMPLETED	Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)
NCT00289042	PHASE4	COMPLETED	Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
NCT00313443	PHASE4	COMPLETED	Concentrations of Amiodarone in Fat Tissue During Chronic Treatment
NCT00340314	PHASE4	COMPLETED	A Trial of Circumferential Pulmonary Vein Ablation (CPVA) Versus Antiarrhythmic Drug Therapy in for Paroxysmal Atrial Fibrillation (AF)
NCT00343499	PHASE4	TERMINATED	The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)
NCT00408473	PHASE4	TERMINATED	Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.
NCT00420017	PHASE4	COMPLETED	Prevention of Atrial Fibrillation Following Esophagectomy
NCT00438113	PHASE4	COMPLETED	Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
NCT00446966	PHASE4	COMPLETED	Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery
NCT00449410	PHASE4	COMPLETED	Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients
NCT00466973	PHASE4	WITHDRAWN	Atrial Fibrillation Ablation Device Comparison Study
NCT00511173	PHASE4	COMPLETED	Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm
NCT00512915	PHASE4	COMPLETED	Avoid FFS - Use of the Atrial Pacemaker Lead 1699 With Very Short Tip Ring Spacing to Avoid Far Field Sensing
NCT00552084	PHASE4	COMPLETED	Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation
NCT00559988	PHASE4	TERMINATED	Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
NCT00579098	PHASE4	COMPLETED	The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation
NCT00586287	PHASE4	COMPLETED	Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon
NCT00597077	PHASE4	COMPLETED	Atrial Fibrillation and Congestive Heart Failure Trial
NCT00603317	PHASE4	COMPLETED	Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid
NCT00605748	PHASE4	UNKNOWN	Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins
NCT00643188	PHASE4	COMPLETED	Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF
NCT00678340	PHASE4	COMPLETED	Randomized Trial of Two Ablation Catheters in Paroxysmal Atrial Fibrillation
NCT00680927	PHASE4	COMPLETED	Reveal® XT Performance Trial (XPECT)